Trevarx Biomedical
Trevarx Biomedical, Inc.
Trevarx Biomedical, Inc. is a clinical-stage biotechnology company spun out of the University of Pennsylvania. It focuses on developing a novel radiopharmaceutical platform that combines a diagnostic imaging agent with a targeted therapy to diagnose and treat various forms of cancer.
Products & Team
[18F]Fluorthanatrace ([18F]FTT)
[18F]FTT is a patented PET imaging biomarker developed to measure the expression of the PARP-1 enzyme in tumors. Currently in Phase 2 multi-center trials for breast cancer, it has been used to image over 296 patients, demonstrating consistent results and no adverse events. The company is advancing towards a pre-NDA meeting with the FDA.
It solves the critical clinical problem of accurately identifying cancer patients who are most likely to respond to PARP inhibitor therapy, enabling more precise and effective personalized treatment plans.
Difficulty in predicting patient response to PARP inhibitor therapies using current genomic assays, leading to suboptimal treatment selection and unnecessary patient exposure to potent drugs. There is a need for a reliable biomarker to guide therapy.